

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 50317

Manuscript Type: MINIREVIEWS

Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives

Pellino A *et al.* Molecular characterization of metastatic gastric cancer

Antonio Pellino, Erika Riello, Floriana Nappo, Stefano Brignola, Sabina Murgioni, Selma Ahcene Djaballah, Sara Lonardi, Vittorina Zagonel, Massimo Rugge, Fotios Loupakis, Matteo Fassan

Abstract

Match Overview

2	Crossref 122 words Jan Bornschein, Michael Quante, Matteo Fassan. "Gastric Cancer", Elsevier BV, 2019	2%
3	Internet 104 words crawled on 01-Sep-2019 journals.sagepub.com	2%
4	Crossref 76 words Seung Tae Kim, Razvan Cristescu, Adam J. Bass, Kyoung-Mee Kim et al. "Comprehensive molecular character ...	1%
5	Internet 70 words crawled on 25-May-2019 jamanetwork.com	1%
6	Crossref 65 words "Surgery for Gastric Cancer", Springer Science and Business Media LLC, 2019	1%
7	Internet 63 words crawled on 20-Jul-2017 www.impactjournals.com	1%
8	Internet 58 words crawled on 05-Dec-2018 www.omicsonline.org	1%
9	Internet 57 words crawled on 07-Feb-2019 jcmjournal.com	1%
10	Internet 52 words crawled on 15-Nov-2018 academic.oup.com	1%
11	Internet 49 words crawled on 06-Jul-2016 www.wjgnet.com	1%
12	Crossref 38 words Valentina Gambardella, Tania Tleitas, Andres Cervantes. "Understanding mechanisms of primary resistance to	1%



All

Images

Videos

翻译成中文

关闭取词

30,100 Results

Any time ▾

Treatment options in patients with metastatic gastric ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983446>

Apr 14, 2014 · Core tip: Although palliative chemotherapy have been demonstrated to improve survival and quality of life, the prognosis of patients with **metastatic gastric cancer** remains poor and responses to first-line chemotherapy are partial and heterogeneous. In order to improve the results of currently available **treatments**, remarkable advancements in new **targeted agents** have recently been obtained.

Cited by: 68

Author: Ahmet Bilici

Publish Year: 2014

Advanced gastric cancer: Current treatment landscape and ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768187>

Feb 28, 2016 · Core tip: With the integration of both ramucirumab and trastuzumab, **treatment options** for advanced **gastric cancer** have increased significantly in recent years. Therefore, a reconsideration of **treatment options** and results for **gastric cancer** is necessary. This paper discusses results of phase III trials for both standard chemotherapy and **targeted treatments in metastatic gastric cancer**.

Cited by: 66

Author: Antonia Digkila, Anna Dorothea Wagner

Publish Year: 2016

Current and Future Aspects of Immunotherapy for ...

https://ascopubs.org/doi/full/10.1200/EDBK_236699

Although the understanding of mechanisms of resistance, biologic effects of **therapies**, and pharmacokinetic and pharmacodynamic characteristics has advanced, the failure to identify appropriate predictive biomarkers has limited the success of many **targeted therapies** in esophageal and **gastric cancer**. A deeper knowledge of specific molecular ...

Author: Ramon Andrade De Mello, Florian Lor... Publish Year: 2019

Systemic Therapy in PD-L1-Positive Gastric Cancer ...

<https://www.targetedonc.com/.../systemic-therapy-in-pd-l1-positive-gastric-cancer> ▾

Sep 10, 2018 · The Journal of Targeted Therapies in Cancer. ONCAAlert | Upfront Therapy for mRCC. ... It's just information for future exploration and study. So, in the second-line setting, that is not the standard of care. ... A 61-Year-Old Woman With Stage 4 Gastric Cancer.

Targeted therapy for gastric cancer - Current status ...

<https://www.researchgate.net/publication>



国内版

国际版

Targeted therapies in metastatic gastric cancer: Current knowledge and future pe



All

Images

Videos

关闭取词

14,300 Results

Any time ▾

Advanced gastric cancer: Current treatment landscape and ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768187>

Feb 28, 2016 · Core tip: With the integration of both ramucirumab and transtuzumab, **treatment** options for advanced **gastric cancer** have increased significantly in recent years. Therefore, a reconsideration of **treatment** options and results for **gastric cancer** is necessary. This paper discusses results of phase III trials for both standard chemotherapy and **targeted treatments in metastatic gastric cancer**.

Cited by: 65

Author: Antonia Digkila, Anna Dorothea Wagner

Publish Year: 2016

Treatment options in patients with metastatic gastric ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983446>

Apr 14, 2014 · Core tip: Although palliative chemotherapy have been demonstrated to improve survival and quality of life, the prognosis of patients with **metastatic gastric cancer** remains poor and responses to first-line chemotherapy are partial and heterogeneous. In order to improve the results of currently available **treatments**, remarkable advancements in new **targeted** agents have recently been obtained.

Cited by: 68

Author: Ahmet Bilici

Publish Year: 2014

Systemic Therapy in PD-L1-Positive Gastric Cancer ...

<https://www.targetedonc.com/.../systemic-therapy-in-pd-l1-positive-gastric-cancer> ▾

Sep 10, 2018 · The Journal of **Targeted Therapies in Cancer**. ONCALert | Upfront **Therapy** for mRCC. ... It's just information for **future** exploration and study. So, in the second-line setting, that is not the standard of care. ... A 61-Year-Old Woman With Stage 4 **Gastric Cancer**.

Treatment of Advanced Gastric & GEJ Cancers | OncLive

<https://www.onclive.com/insights/gastric-gej-cancer-perspectives> ▾

Practical **Perspectives** on **Treatment** of Advanced **Gastric/GEJ Cancers**. ... Goals of **Therapy** in **Metastatic Gastric/GEJ Cancer** ... Dr. Esteva on the **Future** of Biosimilars in **Breast Cancer** .

Molecular targeted therapy of cancer: The progress and ...

<https://www.sciencedirect.com/science/article/pii/S2542364917300596>

Cancer has become a major public health problem worldwide. Researches focus on the new approaches for **cancer treatments** that involve the specific targets of the **cancer** disease. The premise of **targeted therapy** in oncology is the fundamental reliance of tumor cells on biological pathways to which drugs inhibiting those pathways can be applied.

Cited by: 19

Author: Xing Ke, Lisong Shen